Exelixis Inc
(NASDAQ:EXEL)
$17.76
0.47[2.72%]
At close: Feb 8
$17.86
0.1000[0.56%]
After Hours: 7:52PM EDT
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary

Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.

Loading...
Day Range16.990 - 17.93052 Wk Range14.870 - 23.400Open / Close17.000 / 17.760Float / Outstanding285.391M / 324.087M
Vol / Avg.3.425M / 2.323MMkt Cap5.756BP/E31.71450d Avg. Price16.650
Div / Yield (Forward)- / -%Payout Ratio-Total Float285.391MEPS0.960
PRNewswire - Dec 1, 2022, 6:23AM
StockNews - Jan 30, 2023, 2:59AM
TipRanks - Jan 20, 2023, 9:45AM
InvestorPlace - Jan 18, 2023, 3:44PM
TipRanks - Jan 11, 2023, 7:25AM
TipRanks - Jan 6, 2023, 8:46PM
InvestorPlace - Dec 29, 2022, 11:30AM
StockNews - Dec 21, 2022, 5:07AM
InvestorPlace - Nov 29, 2022, 8:30PM
InvestorsObserver - Nov 29, 2022, 2:32PM
Seeking Alpha - Nov 7, 2022, 7:08AM
InvestorsObserver - Nov 2, 2022, 2:58PM
InvestorPlace - Oct 31, 2022, 7:20PM
InvestorPlace - Oct 18, 2022, 4:00PM
Sector: Health Care.Industry: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-09
REV
Q4 2022Est.ActualSurprise
EPS-0.120-0.030 0.0900
REV417.500M423.917M6.417M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Exelixis (EXEL) stock?

A

You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Exelixis (EXEL) stock?

A

The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Exelixis (EXEL)?

A

The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Exelixis (EXEL) pay a dividend?

A

There are no upcoming dividends for Exelixis.

Q

When is Exelixis (NASDAQ:EXEL) reporting earnings?

A

Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.

Q

Is Exelixis (EXEL) going to split?

A

There is no upcoming split for Exelixis.

Q

What sector and industry does Exelixis (EXEL) operate in?

A

Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.